Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults

Elena Ferrer, Luis Del Rio, Esteban Martínez, Jordi Curto, Pere Domingo, Esteban Ribera, Eugenia Negredo, Joaquim Rosales, Maria Saumoy, Jordi Ordóñez, Josep M. Gatell, Daniel Podzamczer

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Changes in body fat distribution in virologically suppressed HIV-infected patients switching from lopinavir/ritonavir (LPV/r) to atazanavir/ritonavir (ATV/r) were assessed. A prospective comparative study was conducted of 37 patients receiving LPV/r regimens switching to ATV/r with 46 patients continuing with LPV/r. Body composition was assessed with whole-body dual-energy X-ray absorptiometry (DXA). Abdominal CT scans were also performed in a subset of patients. Groups were comparable in baseline demographic, clinical, and anthropometric characteristics. After 12 months, peripheral fat did not change significantly, but an increase in trunk fat was observed only in the ATV/r group (0.87 kg, p = 0.021). The percentage of patients with an increase ≥20% in total fat was 37.8% and 15.2% in the ATV/r and LPV/r groups, respectively (p = 0.018). In the ATV/r group, the increase in trunk fat (9.4%) was significantly higher than in peripheral fat (3.7%) (p = 0.007), leading to a significant increase in fat mass ratio (3.76%, p = 0.028), whereas no significant differences were found among LPV/r patients. CT scans showed that abdominal fat increase corresponded to both visceral (28%, p = 0.008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral. © 2011, Mary Ann Liebert, Inc.
Original languageEnglish
Pages (from-to)1061-1065
JournalAIDS Research and Human Retroviruses
Volume27
Issue number10
DOIs
Publication statusPublished - 1 Oct 2011

Fingerprint Dive into the research topics of 'Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults'. Together they form a unique fingerprint.

Cite this